John Castle's Biography

John Castle, CSO, Achilles Therapeutics

We’re defining a new therapeutic paradigm where NGS, bioinformatics, and immunomics are used to generate individualized therapies manufactured on-demand for patients. Originally trained in physics, I moved to Rosetta Inpharmatics, later part of Merck Sharp and Dohme (MSD), where I contributed to the development of novel computational biology, lab and genomic platforms for novel drug targets and biomarkers. At BioNTech and Agenus, I built genomics and computational immunology departments focused on novel cancer immunotherapies, resulting in clinical trials of individualized neoantigen vaccines. At Achilles, we’re pushing the boundaries to rapidly design and manufacture novel, custom-made neoantigen-targeting therapies.